Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Ulthera filed for a U.S. initial public offering yesterday, saying it hopes to raise as much as $86 million when it debuts on the NASDAQ stock exchange.
Mesa, Ariz.-based Ulthera makes an ultrasound device, which is designed to use the body’s natural healing process to non-invasively lift and tighten loose skin on the neck and under the chin. Read more
MASSDEVICE ON CALL — Dr. George Bakris, the co-principal investigator for Medtronic’s failed Symplicty-3 renal denervation trial, believes further clinical work should be tabled until a few key questions about the therapy are answered.
Bakris, in a commentary for MedScape.com, said there’s no question that renal denervation works, citing the therapy’s 40-year history of study. But the failure of the Symplicity-3 trial to meet its efficacy endpoint raises important questions about how to use renal denervation for hypertension, he said. Read more
A federal appeals court today put a hold on the impending ban on U.S. sales of Medtronic’s CoreValve replacement heart valve “pending further notice,” as Medtronic’s patent infringement war with rival Edwards Lifesciences and its competing Sapien valve grinds on.
Earlier this month Judge Gregory Sleet of the U.S. District Court for Delaware granted a preliminary injunction to Edwards, limiting U.S. sales of the CoreValve transcatheter aortic heart implant to patients deemed unsuitable for Edwards’ rival Sapien device Read more